Travoprost Intracameral Implant Reduces Glaucoma Treatment Burden Through 36 Months - Ophthalmology Advisor Researchers compared the medication burden of an intracameral implant and a topical IOP-lowering drop.

#AAO2025: A sustained-release #Travoprost intracameral implant significantly reduced the need for topical #IOP–lowering medications compared with timolol through 36 months in patients with open-angle #Glaucoma or #OcularHypertension. Presented at AAO 2025.

Read more: https://bit.ly/3L1ELy0

#MedSky

Sagent Pharmaceuticals Enters Ophthalmic Market with Launch of Travoprost Solution Sagent Pharmaceuticals has officially entered the ophthalmic sector by launching Travoprost, an innovative solution aimed at lowering eye pressure.

Sagent Pharmaceuticals Enters Ophthalmic Market with Launch of Travoprost Solution #United_States #Schaumburg,_Illinois #Sagent_Pharmaceuticals #Travoprost #Ophthalmic_Solution